Question Bank › Richer on arrival: the business now flowing in c

Richer on arrival: the business now flowing in carries better economics than the blend the numbers show

Calls Tested
497
Answered YES
25
Hit Rate
5%
rare by design

VolitionRx Limited (VNRX) — this company's answers

NO on the Q1 2022 call 2022-05-12 F
The model's full reasoning — Q1 2022 call → NOWe need answer YES/NO based on transcript. Need determine if management conveys both halves. Let's analyze. Transcript: VolitionRx Q1 2022. Key: Heska licensing/supply agreement signed March 28, 2022, $10M upfront received, deferred revenue. Tom Butera explains deal: milestone payments, ongoing revenue from kits/components. "Every time Heska sells a test, Volition will make money... ongoing revenue could be significant." Launch possibly later this year or early 2023. SAGE launched Nu.Q Vet Cancer Test in Singapore. Revenue Q1 $114k vs $25k, from initial sales Nu.Q Discover, Nu.Q Vet to SAGE, H3.1 Q. Net loss $7.7M. Operating expenses increased due to personnel, stock comp. R&D lower. Question: Does management convey that business NOW ARRIVING OR RAMPING carries BETTER ECONOMICS than blended results? And reported numbers understate because mix with older base or costs of scaling? Need see if management says incoming business is economically richer than existing base. They talk about Heska deal: milestone payments $28M, ongoing revenue from kits/components. But is that "arriving" now? The deal signed, upfront received, but revenue not recognized. Launch later this year/early 2023. SAGE launched in Singapore, sales of Nu.Q Vet tests. But do they indicate better economics? They say ongoing revenue could be significant, but not necessarily better margins than existing. They don't compare to existing blend. They mention revenue increased from $25k to $114k, but that's small. They don't say new business has better economics than old. They talk about milestones and ongoing revenue, but that's future. Also deferred revenue due to ASC 606, so reported numbers don't show it. But is that "lagging blend"? They say payment received but not recognized as revenue, accounted as deferred revenue. That is a timing issue. But do they say reported numbers understate because new business is small share or costs of scaling? They mention increased expenses due to headcount, stock comp. Not specifically costs of ramping new business. They say "we continue to manage costs carefully, overall level of expenditure increased... primarily result of increased expenditures in sales and marketing and G&A, mainly due to higher personnel costs...

← Back to the full VNRX analysis

Show the exact prompt the model was given
Using ONLY the supplied earnings call transcript and no outside information: On this call, does management convey that the business NOW ARRIVING OR RAMPING at the company carries BETTER ECONOMICS than the blended results being reported — and that the reported numbers understate the company because they mix this richer incoming business with an older, lower-economics base or with temporary costs of scaling into it? Answer YES when management's own words convey, in whatever form fits the business, BOTH halves of ONE coherent story as a present-tense reality: (1) THE INCOMING BUSINESS IS REAL AND ECONOMICALLY RICHER. Management describes business that is actually arriving, ramping, or recently begun — real orders, customers, contracts, volumes, locations, products, or activity now flowing, not pipeline, hopes, or market opportunity — AND indicates that this newer business is economically better for the company than the base it is joining: better margins, better pricing or terms, lower cost to serve, faster payback, richer mix, better unit economics, or profitability the older business did not have. The comparison must be against the company's OWN existing or reported blend, expressed in whatever terms fit the industry, and grounded in what is actually being earned or booked now rather than in targets or models. (2) THE REPORTED NUMBERS ARE A LAGGING BLEND, AND MANAGEMENT SAYS SO. Management conveys, directly or plainly in substance, that the results being reported do not yet show these richer economics — because the new business is still a small share of the mix, because it began recently or mid-period, or because current results also carry identifiable costs of ramping, scaling, onboarding, or standing up that new business ahead of its revenue — so that as the mix naturally shifts and the ramp matures, results improve from what is already in motion rather than from anything still to be won. Answer NO if the improved economics are only targeted, planned, modeled, or hoped for rather than already being realized on real incoming business. NO if the better economics come chiefly from passing through cost inflation, favorable commodity or market prices the company passively receives, or one-time items. NO if the new business is described but management gives no indication it is economically better than the existing blend. NO if the richer business is already the dominant share of results, with no meaningful mix shift or ramp still ahead. NO if the company is chiefly explaining weakness, cutting costs on a shrinking business, or defending a struggling core. NO if the improvement depends mainly on market recovery, new demand not yet secured, or decisions not yet made. NO if the idea appears only in an analyst's question or model that management does not itself affirm. Use only the supplied transcript. Answer only YES or NO.

Companies that answered YES

TickerCompanyCallDateCall grade
ECPG Encore Capital Group, Inc. Q1 2024 2024-05-08 B
ASB Associated Banc-Corp Q1 2024 2024-04-25 A
HUYA HUYA Inc. Q4 2023 2024-03-19 C
GIII G-III Apparel Group, Ltd. Q4 2024 2024-03-14 C
AKYA Akoya Biosciences, Inc. Q2 2023 2023-08-07 C+
SPT Sprout Social, Inc. Q2 2023 2023-08-04 B+
CTO CTO Realty Growth, Inc. Q2 2023 2023-07-28 B
GVP GSE Systems, Inc. Q1 2023 2023-05-15 D
CARS Cars.com Inc. Q1 2023 2023-05-06 B
CRBG Corebridge Financial, Inc. Q4 2022 2023-02-22 B
TMCI Treace Medical Concepts, Inc. Q2 2022 2022-08-13 B+
FLR Fluor Corporation Q2 2022 2022-08-05 D
OGI OrganiGram Holdings Inc. Q3 2022 2022-07-14 B+
BFIN BankFinancial Corporation Q1 2022 2022-05-06 A
LC LendingClub Corporation Q4 2021 2022-01-26 A
EHTH eHealth, Inc. Q2 2021 2021-07-29 F
ADSK Autodesk, Inc. Q3 2019 2018-11-20 A
CUBI Customers Bancorp, Inc. Q3 2018 2018-10-26 C+
ESS Essex Property Trust, Inc. Q2 2018 2018-08-03 B+
IRT Independence Realty Trust, Inc. Q2 2018 2018-08-02 B
SATS EchoStar Corporation Q1 2018 2018-05-10 C+
ALLY Ally Financial Inc. Q1 2018 2018-04-26 B+
ATI Allegheny Technologies Incorporated Q1 2018 2018-04-24 B
FLEX Flex Ltd. Q1 2018 2017-07-28 F
DAN Dana Incorporated Q1 2017 2017-05-02 B

How the model reasoned

SPT · Q2 2023 → YESThe question is about whether management conveys that the incoming business has better economics than the blended results, and that reported numbers understate the company because they mix richer inco...YES Management describes real, incoming business (enterprise growth to 43% of ARR, Tagger acquisition, premium attach rates, mid-market unit economics) that is economically richer than the existing blend, with deprioritization of lower-quality low-end ARR.
AKYA · Q2 2023 → YESThe question is: Does management convey that the business NOW ARRIVING OR RAMPING at the company carries BETTER ECONOMICS than the blended results being reported — and that the reported numbers unders...
CRBG · Q4 2022 → YESThe question is: Does management convey that the business NOW ARRIVING OR RAMPING at the company carries BETTER ECONOMICS than the blended results being reported — and that the reported numbers unders...

More from the question bank

Doing it our way nowSelling out of one thing at a timeThe lull that never cameCrossed from claiming to demonstratingFixed price, unfixed volumeEverything is being bought forwardAll questions →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our methodology.